236 results on '"Rook, Jerri"'
Search Results
2. Development of a Selective and High Affinity Radioligand, [3H]VU6013720, for the M4 Muscarinic Receptor
3. Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment of Pulmonary Arterial Hypertension
4. Further Optimization of the mGlu1 PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685.
5. Discovery of VU6024578/BI02982816: An mGlu1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models.
6. Discovery of 4‑(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5.
7. Discovery of VU6024578/BI02982816: An mGlu1Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models
8. Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).
9. Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup Candidate.
10. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift
11. Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor
12. M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons
13. Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents
14. mGlu1 and mGlu5 modulate distinct excitatory inputs to the nucleus accumbens shell
15. M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition
16. Development of a Selective and High Affinity Radioligand, [3H]VU6013720, for the M4Muscarinic Receptor
17. M1 Positive Allosteric Modulators Enhance Domains of Cognitive Function by Activation of ssT-expressing Interneurons in the Prefrontal Cortex
18. Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism
19. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents
20. Allosteric activation of M₄ muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice
21. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction
22. Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism
23. Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity
24. Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function
25. Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor
26. CB2 Receptor Potentiation Mediates Antipsychotic‐like Efficacy in Mice
27. Development of Novel M4 Muscarinic Acetylcholine Receptor Antagonists for the Treatment of Movement Disorders
28. Hyperactive Striatal Dopamine Signaling Observed in Huntington’s Disease Mouse Models Prior to Motor Symptom Onset Can be Attenuated via Activation of M 4 Receptors
29. Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity
30. Discovery and optimization of a novel CNS penetrant series of mGlu4 PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model
31. Morphine-induced early delays in wound closure: Involvement of sensory neuropeptides and modification of neurokinin receptor expression
32. Discovery of “Molecular Switches” within a Series of mGlu5 Allosteric Ligands Driven by a “Magic Methyl” Effect Affording Both PAMs and NAMs with In Vivo Activity, Derived from an M1 PAM Chemotype
33. Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist
34. Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy
35. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release
36. Functional activity of the muscarinic positive allosteric modulator VU319 during a Phase 1 Single Ascending Dose study
37. Allosteric Modulation of Metabotropic Glutamate Receptors
38. A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypes
39. Cognitive performance effects following a single dose of the M 1 muscarinic positive allosteric modulator VU319
40. Safety and pharmacokinetics of the muscarinic positive allosteric modulator VU319: A phase 1 single dose study
41. Discovery of the first selective M4muscarinic acetylcholine receptor antagonists within vivoanti-parkinsonian and anti-dystonic efficacy
42. FUNCTIONAL ACTIVITY OF THE MUSCARINIC POSITIVE ALLOSTERIC MODULATOR VU319 DURING A PHASE 1 SINGLE ASCENDING DOSE STUDY
43. The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core
44. Biased M 1 receptor–positive allosteric modulators reveal role of phospholipase D in M 1 -dependent rodent cortical plasticity
45. Biased M1positive allosteric modulators reveal novel role of phospholipase D in M1-dependent rodent cortical plasticity
46. P4‐681: OPTIMIZATION OF NOVEL M1 PAMS FOR CLINICAL DEVELOPMENT WITH ENHANCED EFFICACY WHILE AVOIDING ADVERSE EFFECT LIABILITY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
47. Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound
48. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release
49. VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events
50. Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M1Positive Allosteric Modulators
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.